Neoadjuvant and Adjuvant Tislelizumab for Nasopharyngeal Carcinoma

NCT05211232 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

450

Enrollment

OTHER

Sponsor class

Conditions

Nasopharyngeal Carcinoma

Interventions

DRUG: Tislelizumab
DRUG: Placebo

Sponsor

Sun Yat-sen University

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]